Published in Int J Cell Biol on October 27, 2013
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol (2016) 1.40
Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res (2015) 1.06
Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol (2015) 1.01
Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer. Trends Pharmacol Sci (2015) 0.96
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene (2015) 0.88
DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. Sci Rep (2016) 0.88
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet (2015) 0.85
Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci (2014) 0.82
Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage. Nucleic Acids Res (2015) 0.82
Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy. PLoS Genet (2016) 0.82
Relevance of splicing on tumor-released exosome landscape: implications in cancer therapeutics. Front Endocrinol (Lausanne) (2014) 0.81
SAM68: Signal Transduction and RNA Metabolism in Human Cancer. Biomed Res Int (2015) 0.81
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J (2015) 0.79
Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells. Cell Commun Signal (2014) 0.78
A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor. Int J Clin Exp Pathol (2014) 0.78
ATRA modulates mechanical activation of TGF-β by pancreatic stellate cells. Sci Rep (2016) 0.77
Molecular signaling involving intrinsically disordered proteins in prostate cancer. Asian J Androl (2016) 0.77
Alternative RNA splicing: contribution to pain and potential therapeutic strategy. Drug Discov Today (2016) 0.76
Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment. Biomed Res Int (2016) 0.75
Splicing Regulators and Their Roles in Cancer Biology and Therapy. Biomed Res Int (2015) 0.75
Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers. Clin Transl Med (2014) 0.75
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. Oncoscience (2015) 0.75
EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer (2017) 0.75
The landscape of alternative splicing in cervical squamous cell carcinoma. Onco Targets Ther (2014) 0.75
Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma. BMC Genomics (2016) 0.75
Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics (2016) 0.75
Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems. Hum Genet (2017) 0.75
Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers. HIV AIDS (Auckl) (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Alternative isoform regulation in human tissue transcriptomes. Nature (2008) 52.76
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet (2008) 24.51
Cancer metastasis: building a framework. Cell (2006) 19.67
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 9.13
Expansion of the eukaryotic proteome by alternative splicing. Nature (2010) 8.84
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev (2009) 5.61
Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3' ends. Cell (1980) 5.59
RNA processing and its regulation: global insights into biological networks. Nat Rev Genet (2010) 5.34
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev (2010) 4.75
Life at the leading edge. Cell (2011) 4.42
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 3.41
Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature (2002) 3.17
Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta (2005) 3.06
The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol (2008) 3.05
Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol (2009) 2.90
The role of hypoxia-induced factors in tumor progression. Oncologist (2004) 2.87
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell (2005) 2.85
CD44 in cancer. Crit Rev Clin Lab Sci (2002) 2.83
Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer (2007) 2.79
Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell (2011) 2.77
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell (2008) 2.65
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A (2003) 2.65
Epithelial-mesenchymal transitions: insights from development. Development (2012) 2.58
The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51
CD44, a therapeutic target for metastasising tumours. Eur J Cancer (2010) 2.50
The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46
Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev (2011) 2.45
An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J (2010) 2.42
Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Mol Cell Biol (2004) 2.36
Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem (2004) 2.26
Dynamic integration of splicing within gene regulatory pathways. Cell (2013) 2.25
Rac1 GTPase: a "Rac" of all trades. Cell Mol Life Sci (2009) 2.19
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci (2008) 2.09
Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta (2003) 2.08
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res (2006) 2.06
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell (2011) 2.06
Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci (2011) 2.00
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97
Multiple alternative splicing markers for ovarian cancer. Cancer Res (2008) 1.93
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction (2010) 1.86
Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res (2004) 1.85
Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev (2009) 1.85
N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci (2012) 1.84
Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene (1999) 1.82
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res (2008) 1.79
Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med (2012) 1.76
An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res (2011) 1.75
Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res (2007) 1.73
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun (2012) 1.71
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem (2009) 1.68
Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med (2012) 1.67
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65
Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res (2007) 1.65
Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis (2008) 1.64
VEGF and endothelial guidance in angiogenic sprouting. Organogenesis (2008) 1.63
Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem (2003) 1.60
Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene (2003) 1.59
The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol (2009) 1.57
Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol (2010) 1.55
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med (2013) 1.53
Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol (2010) 1.53
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer (1994) 1.51
CCN proteins and cancer: two to tango. Front Biosci (2005) 1.50
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A (2011) 1.48
Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene (2013) 1.48
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem (2005) 1.47
Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology (2001) 1.46
Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci U S A (2005) 1.45
Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer (2004) 1.45
The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J Biol Chem (2008) 1.43
Alternative splicing and tumor progression. Curr Genomics (2008) 1.43
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res (2006) 1.41
MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell (2011) 1.41
Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet (2012) 1.39
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell (2005) 2.85
Transcriptional activation of a constitutive heterochromatic domain of the human genome in response to heat shock. Mol Biol Cell (2003) 1.79
Cellular response to etoposide treatment. Cancer Lett (2006) 1.61
Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res (2007) 1.58
Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol (2010) 1.55
Structural and functional characterization of noncoding repetitive RNAs transcribed in stressed human cells. Mol Biol Cell (2005) 1.47
Modular structure of the human lamin B2 replicator. Mol Cell Biol (2004) 1.46
Alternative splicing and tumor progression. Curr Genomics (2008) 1.43
Human chromosomes 9, 12, and 15 contain the nucleation sites of stress-induced nuclear bodies. Mol Biol Cell (2002) 1.23
Early mitotic degradation of the homeoprotein HOXC10 is potentially linked to cell cycle progression. EMBO J (2003) 1.16
Functional interactions of DNA topoisomerases with a human replication origin. EMBO J (2007) 1.14
A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA (2004) 1.14
RNA recognition motif 2 directs the recruitment of SF2/ASF to nuclear stress bodies. Nucleic Acids Res (2004) 1.13
Subnuclear distribution of the largest subunit of the human origin recognition complex during the cell cycle. J Cell Sci (2004) 1.12
The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway. Cancer Res (2006) 1.07
DNA ligase I deficiency leads to replication-dependent DNA damage and impacts cell morphology without blocking cell cycle progression. Mol Cell Biol (2009) 1.04
Cell cycle-dependent phosphorylation of human DNA ligase I at the cyclin-dependent kinase sites. J Biol Chem (2003) 1.04
Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. EMBO J (2002) 1.03
Constitutive heterochromatin: a surprising variety of expressed sequences. Chromosoma (2009) 1.01
HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res (2013) 1.00
Molecular and structural transactions at human DNA replication origins. Cell Cycle (2007) 0.98
Human rpL3 induces G₁/S arrest or apoptosis by modulating p21 (waf1/cip1) levels in a p53-independent manner. Cell Cycle (2012) 0.98
Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol (2010) 0.97
hnRNP H1 and intronic G runs in the splicing control of the human rpL3 gene. Biochim Biophys Acta (2010) 0.97
Autoregulatory circuit of human rpL3 expression requires hnRNP H1, NPM and KHSRP. Nucleic Acids Res (2011) 0.95
Pre-mRNA processing factors meet the DNA damage response. Front Genet (2013) 0.92
Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT). Cell Mol Life Sci (2012) 0.91
Transcription of Satellite DNAs in Mammals. Prog Mol Subcell Biol (2011) 0.90
Endoscopic endonasal transpterygoid transmaxillary approach to the infratemporal and upper parapharyngeal tumors. Otolaryngol Head Neck Surg (2014) 0.88
DNA replication, development and cancer: a homeotic connection? Crit Rev Biochem Mol Biol (2010) 0.87
Acquired tracheal dilatation after prolonged ventilation: an unusual treatment option. Laryngoscope (2014) 0.87
SAFB re-distribution marks steps of the apoptotic process. Exp Cell Res (2007) 0.86
Phosphorylation of SRSF1 is modulated by replicational stress. Nucleic Acids Res (2011) 0.85
Homeotic proteins participate in the function of human-DNA replication origins. Nucleic Acids Res (2010) 0.85
Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer. Int J Cell Biol (2013) 0.84
Endoscopic endonasal nasopharyngectomy in selected cancers. Otolaryngol Head Neck Surg (2013) 0.84
Alternative splicing and muscular dystrophy. RNA Biol (2010) 0.83
CorrelaGenes: a new tool for the interpretation of the human transcriptome. BMC Bioinformatics (2014) 0.81
Alternative splicing and cancer. J Nucleic Acids (2012) 0.77
DNA ligase I and Nbs1 proteins associate in a complex and colocalize at replication factories. Cell Cycle (2009) 0.76
A novel endoscopic technique for long-term patency of cholesterol granulomas of the petrous apex. Laryngoscope (2013) 0.76
A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene. Oncol Rep (2013) 0.75
Management of chronic rhinosinusitis. Pediatr Allergy Immunol (2012) 0.75
DNA-protein interaction dynamics at the Lamin B2 replication origin. Cell Cycle (2015) 0.75
Alternative splicing of tumor suppressors and oncogenes. Cancer Treat Res (2013) 0.75
Oncocytic Schneiderian papillomas: Clinical behavior and outcomes of the endoscopic endonasal approach in 33 cases. Head Neck (2013) 0.75